Market Overview

FDA Issues Review of Hemispherx's Ampligen Lacks Required Carcinogencity Tests

Share:
Related HEB
Hemispherx BioPharma CEO Talks Stock Performance, Financials And Partnerships
Hemispherx BioPharma CEO Talks About Ampligen, Alferon's Potential

View document.

Posted-In: News FDA

 

Related Articles (HEB)

View Comments and Join the Discussion!